Angioplasty balloons and stents are specially designed tiny tools that doctors use to fix clogged pipes in our hearts or other blood vessels. When arteries get blocked, it can cause serious problems. Angioplasty balloons are like mini balloons that doctors put into the blocked area and inflate to squish the gunk and widen the pipe. Stents are like little metal or drug-coated tubes that are often placed after the balloon to keep the pipe open and stop it from getting clogged again. These tools help blood flow better and can prevent heart attacks and other complications. They are utilized in procedures known as percutaneous transluminal angioplasty (PTA) and percutaneous coronary intervention (PCI), respectively.
Balloon angioplasty was limited by unpredictable procedural outcomes due to vessel dissection and recoil, and a high rate of restenosis. The introduction of stents resulted in more stable early results and lower rates of restenosis, although early stent thrombosis and neointimal hyperplasia causing vessel re-narrowing were key limitations. Drug-eluting stents delivering antiproliferative agents significantly lowered the rates of restenosis, permitting widespread use of percutaneous coronary intervention in more advanced and complex diseases. Although fully bioresorbable scaffolds have the potential to further improve long-term outcomes, they have not yet achieved results equivalent to those of conventional metallic drug-eluting stents in the early years after implantationAngioplasty balloons are often used to fix narrow or blocked blood vessels, like those in the heart (CAD) or other parts of the body (PAD). They help widen the vessels, improving blood flow and reducing problems caused by blockages. Stents are like little tubes that doctors put in your arteries to keep them open after fixing a blockage. They help stop the artery from getting narrow again, which could cause more problems. Stents are used in both heart and other artery procedures to keep things flowing smoothly and lower the chances of more blockages.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/angioplasty-balloons-and-stents-market/
Global Angioplasty Balloons and Stents Market – Competitive Insights
- On December 11, 2022, Boston Scientific bought a majority stake of 65% in Chinese medical technology firm Acotec Scientific for $523 million. Acotec Scientific develops medical instruments, including DCB & percutaneous transluminal angioplasty balloon catheters (PTA). The company has a DCB product portfolio with 5 therapeutic target areas such as neurology, cardiology, andrology & vascular surgery.
- On March 31, 2021, B. Braun Interventional Systems (BIS) announced that it was collaborating with Infraredx on a trial for the B. Braun SeQuent Please ReX. The SeQuent Please ReX drug-coated PTCA balloon catheter is designed to treat coronary in-stent restenosis (ISR).
Some of the Key Players in the Global Angioplasty Balloons and Stents Market Include –
- Spectranetics Corp
- Becton, Medtronic PLC
- Boston Scientific Corporation
- Cook Medical, Inc.
- Dickinson and Company
- Cardinal Health (Cordis)
- ENDOCOR GmbH
- Johnson & Johnson
- Abbott Laboratories
Global Angioplasty Balloons and Stents Market – Growth Drivers
The global rise in the prevalence of cardiovascular diseases like coronary artery disease, and peripheral artery disease is the main factor driving this market. The geriatric age people are mostly found to be suffering from heart disease. As per the World Health Organization’s estimation, 1 in 6 people at the age of 60 and above will be facing cardiovascular disease by 2030. Cardiovascular risk factors are highly prevalent in some countries like Western Europe, the habits like smoking, and alcohol are increasing day by day. According to the World Heart Federation, the primary cause of death in that region is heart issues. A sedentary lifestyle also leads to inactivity of the body which directly leads to heart disease. Better technology and new ways of doing things help the market grow. When devices like angioplasty balloons and stents get upgrades in how they’re made and what they’re made of, they work better and are safer. This makes doctors more likely to use them, which boosts the market for these products. When insurance and the government help pay for these procedures, more people can afford them. This means doctors can do more of them, which makes the market for these products grow.
Global Angioplasty Balloons and Stents Market – Restraints
The Angioplasty Balloons and Stents Market faces constraints due cost of making such devices. Making better balloons and stents is tough because patients and doctors always want safer and more effective ones. This means companies have to spend a lot on research to keep up and meet the rules. Another big challenge is how expensive healthcare is getting, and how insurance pays for it. As more people need these procedures, hospitals and companies have to find ways to keep costs down without sacrificing quality. Sometimes, insurance doesn’t cover all the costs, which can affect how much hospitals can afford to use these new technologies and how much money companies make selling them. Lots of companies want to sell balloons and stents, so they try to make theirs stand out. They do this by adding special features, setting prices, and showing how well their products work. But they also have to deal with rules and make sure no one copies their ideas. So, the competition between the companies are so high.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/angioplasty-balloons-and-stents-market/
Global Angioplasty Balloons and Stents Market – Opportunities
The increasing global geriatric demographic presents a significant opportunity for the Angioplasty Balloons and Stents market, as age-related factors contribute to a higher prevalence of cardiovascular disease. Making better balloons Investing in research helps companies stay ahead and be better than their competitors. Customizing treatments based on special pictures of the body and checking someone’s genes can help doctors give better treatments for fixing blocked arteries. This could mean fewer problems and better results for patients. Because people care more about getting good value for their money in healthcare, companies can show that their products are worth it by proving they work well and are cheaper than other options. This can convince hospitals and doctors to choose their products more often, helping them sell more.
Global Angioplasty Balloons and Stents Market – Geographical Insight
The market for Angioplasty Balloons and Stents Market is segmented into regions such as North America, Latin America, Europe, Asia-Pacific, the Middle East & Africa. North America is the largest market for Angioplasty Balloons and Stents due to well-established healthcare infrastructure facilities and widespread diagnosis and treatment. Due to the Presence of key market players contributing to research and development in the region. Asia-Pacific rapid urbanization and lifestyle changes contribute to the rising incidence of cardiovascular Disease. A large population increase and increase in geriatric population particularly in countries like China and India, provides a substantial market. Increasing healthcare expenditure and improving healthcare infrastructure enhance market growth prospects.
Global Angioplasty Balloons and Stents Market – Key Development
- On March 23, 2023, in the US, SIS Medical AG introduced the OPN NC PTCA Dilatation Catheter with TWIN-Wall technology. By offering great performance and safety along with success rates where other balloons fail, the product expands therapy possibilities. The OPN NC catheter features a TWIN-Wall design, which offers a super-high-pressure resistance with a rated burst pressure of 35 atm with a significantly low compliance. Stents are a big opportunity.
- On September 19, 2022, Advanced NanoTherapies, Inc. reported the U.S. FDA granted the company a Breakthrough Device designation for its SirPlux Duo Drug-Coated Balloon (DCB) for coronary artery disease in vessels less than 3.0mm.
- On October 24, 2022, Med Alliance’s novel sirolimus-eluting balloon, SELUTION SLR received FDA Investigational Device Exemption (IDE) approval to initiate its coronary pivotal clinical trial.